245 related articles for article (PubMed ID: 27153551)
1. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
2. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
3. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
4. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
5. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
[TBL] [Abstract][Full Text] [Related]
6. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
7. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
[TBL] [Abstract][Full Text] [Related]
8. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
10. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
11. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients.
Wu Y; Huang B; Liu Q; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8252-9. PubMed ID: 26339394
[TBL] [Abstract][Full Text] [Related]
14. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
[TBL] [Abstract][Full Text] [Related]
16. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
17. Adipophilin expression in lung adenocarcinoma is associated with apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases.
Fujimoto M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Hirata M; Momose M; Date H; Haga H
Histopathology; 2017 Jan; 70(2):232-241. PubMed ID: 27467545
[TBL] [Abstract][Full Text] [Related]
18. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma.
Saito H; Yamashita M; Ogasawara M; Yamada N; Niisato M; Tomoyasu M; Deguchi H; Tanita T; Ishida K; Sugai T; Yamauchi K
Hum Pathol; 2016 Apr; 50():1-10. PubMed ID: 26997432
[TBL] [Abstract][Full Text] [Related]
19. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.
Akagi I; Okayama H; Schetter AJ; Robles AI; Kohno T; Bowman ED; Kazandjian D; Welsh JA; Oue N; Saito M; Miyashita M; Uchida E; Takizawa T; Takenoshita S; Skaug V; Mollerup S; Haugen A; Yokota J; Harris CC
Cancer Res; 2013 Jul; 73(13):3821-32. PubMed ID: 23639940
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
